Audrey's Life Science Meeting Picks for March 19, 2017 – June 2017
Complimentary Service of AudreysNetwork.com
March 19, 2017

****

HBA, Monday Evening, March 20, 2017

Event: Fireside Chat: The Future of Medicine with Former NBC Medical Journalist Dr. Nancy Snyderman
Featured speakers: Nancy Snyderman, Consulting global health professor, former otolaryngologist, former chief medical editor, Stanford University; Jennifer Lovejoy, Chief science officer, Arivale; Ramji Srinivasan, Chief executive officer, Counsyl; Darren Brown, Executive vice president, employee benefits, ABD Insurance & Financial Services
Date and time: Monday, 20 March, 5:30PM - 8:30PM PST
Agenda
5:30 - 6:15 PM Registeration and networking
6:15 - 6:25 PM Opening remarks from the HBA
6:25 - 6:30 PM ABD Insurance remarks
6:30 - 6:35 PM Welcome remarks by Counsyl CEO and co-founder, Ramji Srinivasan
6:35 - 7:00 PM The science of wellness by Arivale, CSO Jennifer Lovejoy, PhD
7:00 - 7:45 PM Fireside chat with Dr. Nancy Snyderman
7:45 - 8:15 PM Q&A
8:15 - 8:30 PM Wrap up and closing
Location: Counsyl, 180 Kimball Way, South San Francisco, CA 94080
Registration information
Event is open to: HBA members and nonmembers
Early bird registration deadline: 1 March, 2017
Online registration deadline: 16 March, 2017
Onsite (walk-in) registration: Is allowed
Fees:

Registration Name	Price Level	Early Bird	Regular
1 - Regular registration	Member	$30.00	$40.00
1 - Regular registration	Non-Member	$45.00	$55.00
2 - Counsyl employee registration	Member	$25.00	$35.00
2 - Counsyl employee registration	Non-Member	$25.00	$35.00
3 - Arivale employee registration	Member	$25.00	$35.00
3 - Arivale employee registration	Non-Member	$25.00	$35.00
4 - ABD employee registration	Member	$25.00	$35.00
4 - ABD employee registration	Non-Member	$25.00	$35.00

Cancellations/refunds
Is this event refundable? Yes
If yes, requests must be submitted in writing to events@hbanet.org by 16 March, 2017; no refunds are available after this date.
Details and registration at
https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=37E161F6-32E7-E611-B295-0050569C00A7

Event contact
Parisha Dalia
408-306-1520

Learning objectives

1. Understand the mission and goals of new health tech companies entering the space around genetic screening and the science of wellness
2. Gain valuable insights into how today's big healthcare topics in patient advocacy, big data, wellness, genetic screening and drug pricing will affect patients and practitioners

Registration information
The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.
The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

By registering for this event, you acknowledge that you may be photographed, videotaped and/or audio-taped during the course of the meeting and hereby give permission for your image, voice, or survey comments to be used in education, training, promotion and/or trade and communications media by the Healthcare Businesswomen's Association in any and all media throughout the world, without restriction as to frequency or duration of usage.
Event Description
Please join HBA San Francisco, along with sponsors Counsyl and Arivale for a lively discussion on how healthcare's biggest topics will affect doctors and patients in the future.

Hosted by Counsyl, a health technology company focused on genetic screening, you will hear from Ramji Srinivasan, CEO and co-founder, Counsyl, as well as Jennifer Lovejoy, PhD, CSO, Arivale, who will provide an overview into the science behind wellness. Then, for the main event, guests will enjoy a fireside chat with Dr. Nancy Snyderman, former medical journalist for NBC News. Nancy will draw on her three decades of experience as a head and neck cancer surgeon and medical journalist to provide valuable insights into how the strides being made in wellness, patient advocacy, big data including next generation sequencing and drug pricing will affect the future practice of medicine.

You won't want to miss this unique opportunity to meet and hear from this group of talented and accomplished leaders in health, tech and medicine.
Special instructions: Parking available onsite.

****

EPPICon 2017, Saturday, March 25, 2017

Event: 11th Annual flagship event of EPPIC Global
Keynote Speakers: Ira Mellman, PhD (Genentech) and D. J. Patil (Chief Data Scientist, White House Office of Science and Technology)
Date and Time: Saturday, March 25, 2017,
8:00 AM: Registration open - Breakfast and Networking
9:00 AM: Opening / Plenary Keynote - Ira Mellman, PhD, Genentech
10:30 AM – 5:00 PM: Panels and Speakers
Location: Crowne Plaza Hotel San Francisco Airport, 1177 Airport Blvd, Burlingame, CA 94010
Registration online: $100
On-site Registration: $150
Student/Post Doc Registration Online: $75* (Valid student ID to be presented at Conference)
EPPIC Charter Members** / Sponsors** / Event Speakers**

(Registration includes food and beverage - breakfast, lunch, coffee breaks and evening reception)
* Student/Post Doc promo code "STCON17"
** Renew or Register with Code provided to you: Conference is complimentary
Register at
https://s07.123signup.com/servlet/SignUpMember?PG=1536045182300&P=15360451911431663100
Visit www.eppicon.org for more information

Event Description
Since 1998, EPPIC Global has been serving the San Francisco Bay Area life sciences community promoting entrepreneurship, networking, partnering, and mentoring. Join us to hear expert talks and panel discussions on

Immunotherapy, Bioinformatics and Diagnostics
If targeted therapies and personalized medicine revolutionized cancer treatment in the last decade, will Immunotherapy be the next big hope during the coming decade?
Have we finally got a handle on big data and where is Bioinformatics headed?
Ditto with regard to Biomarkers and Diagnostics?

Advances in cancer immunotherapy have generated enthusiasm across all fields of oncology. Complimentary/companion diagnostics along with predictive biomarkers are integral to improving patient outcome. In addition, emphasis on personalized medicine and targeted therapies, diagnostics and biomarkers are playing an increasingly important role in drug development. Early adoption of bioinformatics tools can help advance therapeutic candidates.

EPPICon 2017 continues the grand tradition of bringing you the latest advances and opportunities in science and technology.
Get updated on the state of the art in science and business
Form new alliances
Explore investment opportunities

Who Should Attend
Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health

OPEN for Registration NOW!!!
Click here to Register

Immuno-Oncology Panel: Chan Whiting, PhD, Aduro Biotech, Robert Sikorski, MD, PhD, Five Prime Therapeutics, Caroline Breitbach, PhD, Turnstone Biologics, Alex Franzusoff, PhD, PACT Pharma
Bioinformatics Keynote Speaker: Nikesh Kotecha, PhD
Bioinformatics Panel:Arshad Ahmad, Ajay Shah, Richard Bourgan, PhD, Genentech
Devices/Diagnostics: Speaker to be announced
Speed Pitch (Please see below for details)

11:30 AM – 1:15 PM: Speed Networking, Vendor Exhibit and Lunch

5:00 PM: Closing Keynote – D. J. Patil, Chief Data Scientist, White House Office of Science and Technology

Evening Reception and Networking
****

CABS, Saturday Afternoon, March 25, 2017

Topic: "Precision Medicine for oncology and immunology"
Date and Time: Saturday March 25, 2017 @ 2:00 pm - 4:00 pm
Location: Hanqi Investment, 1633 Bayshore Hwy, Unit 280, Burlingame, CA 94010
Free
Register at
http://www.cabsweb.org/registration/2455518/Precision%20Medicine%20for%20oncology%20and%20immunology/

Presentations:
1. Liquid biopsies in precision drug development by Shidong Jia, Founder and CEO of Predicine Holdings Ltd.
Cancer immunotherapy and targeted therapy offer great promise in precision oncology, where predictive biomarkers have been extensively investigated in various types of cancer patients. The talk will describe development and clinical application of an innovative, next generation sequencing based liquid biopsy test to support cancer immunotherapy clinical trials.

Speaker Bio
Dr. Shidong Jia is the Founder and CEO of Predicine Holdings Ltd, an international precision medicine organization that is committed to developing innovative diagnostics, therapeutics and big data in cancer and other serious diseases. The company operates in California, USA and Shanghai, China. Driven by a passion to improve personalized medicine, Dr. Jia has dedicated the past 21 years to basic, translational, and clinical cancer research. His previous work identified p110beta as novel drug target for PTEN-deficient prostate tumors (Jia S, et al. Nature, 2008), a finding that laid the foundation for the clinical development and testing of p110beta inhibitors in cancers. Most recently, his team at Predicine developed world's first ctRNA and ctDNA combined liquid biopsy test for precision medicine in cancer. A former Scientist, principal investigator and prostate cancer disease area lead at Genentech, Dr. Jia spearheaded the biomarker strategies and drug & diagnostics co-developments efforts in support of clinical oncology pipeline at various stages (i.e., early stage research, late stage research, early clinical development, Phase I and Phase II clinical trials), culminated by the Lifecycle Investment Point (LIP) achievement of driving an investigative drug from global Phase II into Phase III pivotal clinical trial. Prior to joining Genentech, Dr. Jia was Laboratory Head for Oncology Drug Discovery at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Jia serves as the Editor-in-Chief of "Journal of Circulating Biomarkers", Guest Associate Editor of "Frontiers in Oncology", and Members of National Cancer Institute Review Committees and the Italian Ministry of Health - Scientific Research and Health Innovation Review Committee. Dr. Jia is a BayHelix member and receipt of several awards, including the "Young Investigator Award" at the Fourth Asian Congress for Microcirculation in Indonesia and the "P.A.R.T. Investigatorship Award" at the Dana-Farber Cancer Institute, Harvard Medical School in Boston.

2. Towards an Assay of Global Immunocompetence by Holden Maecker, Director, Human Immune Monitoring Center, Stanford

A long-term goal of our laboratory is to define metrics of healthy immune function and the deviations that predict or define disease states. There are many facets of the immune system that can be measured, and few clinically accepted tests of immune function. However, we hypothesize that a comprehensive assessment of the proportions, phenotypes, and functions of specific immune cell subsets in blood should be helpful in defining these metrics. We have therefore defined for this purpose a mass cytometry assay using phorbol myristate acetate (PMA)+ionomycin stimulation of peripheral blood mononuclear cells (PBMC), with staining for approximately 40 cell-surface and intracellular proteins, including lineage markers, cytokines, and other functional markers. Mass cytometry, or CyTOF, is a version of flow cytometry that uses heavy metal ion labels in place of fluorochromes, with readout by time-of-flight mass spectrometry. The CyTOF platform allows for many more labeled antibodies to be used in combination, with much less spillover between detection channels, compared to conventional flow cytometry. In this talk, I will describe this methodology and how we are applying it currently to the monitoring of patients undergoing cancer immunotherapy. Our goal in these studies is to better tailor immunotherapies to specific patients, and to suggest approaches that might be useful to address those patients with suboptimal immune function.

Speaker Bio
Dr. Holden T. Maecker received his PhD from Stanford University, is currently Assoc. Prof. at Microbiology & Immunology department and Director of Human Immune Monitoring Center at Stanford. His research is in the area of T cell response signatures and their association with protection from chronic pathogens and cancer. His lab has published a number of papers on this topic, both alone and in collaboration with other groups, in systems such as CMV, HIV, tuberculosis, and cancer. The Human Immune Monitoring Center (HIMC) is a Stanford core service laboratory, which performs blood processing and standardized assays using flow cytometry, genomics, and immunoassay platforms. For the past five years, his lab has gained extensive experience with CyTOF mass cytometry. In addition to being PI on multiple NIH, industry, and foundation grants, Dr. Maecker serves as a core leader for several cooperative center grants and other large collaborative projects, in which he oversees the use of HIMC assays, including data analysis and interpretation.
****

JLABS, Tuesday Morning, March 28, 2017

Topic: "Meet with …MPM Capital "Program Overview:
Speakers: Vinay Bhaskar, Ph.D., Principal with MPM Capital;
Luke Evnin | Managing Director, MPM Capital
Date and Time: Tuesday, March 28, 2017, 10:30 am
Agenda:
10:30am | Registration & Networking
11:00am | Presentation and Q&A
11:45am | Lunch & Networking
12:30-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due February 28. Apply Here.
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco,
Fees:
Presentation
$25 | General Public
$35 | Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until March 28th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on February 28, 2017. Your application will be reviewed and you will be notified of acceptance by March 15, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved. Registration at https://www.eventbrite.com/e/meet-with-mpm-capital-tickets-29590468889?aff=weekly

Topic Description
Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas. MPM is no stranger to Johnson and Johnson Innovation, JLABS (JLABS) with investments that recently helped 3 Bay Area JLABS companies reach the next level. MPM is now investing two funds, BV2014, a $400M fund focusing on early stage companies developing therapies for unmet medical needs (Series A and earlier), and the Oncology Impact Fund, a $470M fund that invests solely in oncology companies of any stage (therapeutics only – no diagnostics). For more information on MPM visit http://www.mpmcapital.com/

Vinay Bhaskar, Ph.D., Principal with MPM Capital, will be in attendance to provide an overview presentation on MPM's key areas of interest and venture investment philosophy. Vin will be joined by Luke Evnin to answer any questions and meet with a handful of applicants for one-on-one meetings. To be considered for a one-on-one meeting complete the information required in the link below.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

Do you have innovation that will change the face of medicine? MPM Capital is looking for leading scientific research that addresses unmet medical needs across all therapeutic areas.

Speaker Bios
Luke Evnin, Ph.D., co-founded MPM with Ansbert Gadicke in 1997 and opened the San Francisco office in 1999. The MPM team they have led has been the inspiration and driving force behind building companies such as Biomarin (BMRN), CoStim

Pharmaceuticals (acquired by Novatris: NVS), Epizyme (EPZM), Idenix (acquired by Merck: MRK), Pacira (PCRX), Pharmasset (acquired by Gilead: GILD) and Radisu (RDUS). MPM believes that these companies are among the biggest successes in biotech history - companies that ultimately resulted in helping thousands of patients live longer with vastly improved lives. Luke was lead investor and has served on the boards of several of MPM's most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira.
Prior to co-founding MPM, Luke honed his skills as a venture capitalist beginning in 1990 at Accel Partners where he focused on emerging healthcare companies. Luke's passion for drug discovery began in college where he received his A.B. in Molecular Biology from Princeton University. He advanced his technical training and launched his interest in curing disease with his doctoral study in Department of Biochemistry at the University of California - San Francisco. Luke's passion for discovering and pushing forward groundbreaking drug discovery companies inspires his work and that of his team. Luke has devoted significant efforts since 2000 to working with Scleroderma Research Foundation, serving as Chairman since 2002. Luke also devotes energy to the External Advisory Board at the Lewis-Sigler Insitiute for Quantitative Gernomics at Princeton, serves on the External Advisory Boards for QB3 at UCSF, the Masters in Translation Medicine program at UCSF, and Boston University Scleroderma CORT.

Vinay Bhaskar, Ph.D., joined MPM in 2016 after leading External R&D for the Oncology therapeutic area at Amgen. In this role, Vin was instrumental in forging collaborations with companies such as Kite Pharma, Merck, and Xencor. During this time he also led internal immuno-oncology strategy discussions and served as executive sponsor and/or board observer for several Amgen Ventures investments, including Surface Oncology, Precision BioSciences and Tizona Therapeutics, a company founded by MPM. Vin joined Amgen through its acquisition of Onyx Pharmaceuticals, where he led preclinical search, evaluation, and diligence for licensing and acquisition opportunities on the Asset Acquisition Team.
Prior to joining Onyx, Vin held a variety of roles of increasing responsibility in Discovery Research at Portola Pharmaceuticals, XOMA, PDL Biopharma and Eos Biotechnology. In these roles, he initiated and led multiple preclinical project teams and functional groups focused on biologies and spanned oncology, inflammation and cardio metabolic disease. Through these endeavors, Vin has gained broad expertise across all phases of drug discovery, early development and process sciences. Vin holds a Ph. D. in Biochemistry from UCLA and a B.S. in Biochemistry from UC Davis.
****

Palo Alto AWIS, Wednesday Evening, March 28, 2017

Topic: "Public Policy and Government Careers for Scientists"
Date and Time: Wednesday, March 28, 2017, 7- 9 PM
7:00-7:30: Networking dinner
7:30-7:45: Announcements
7:45-9:00: Workshop
Location: PARC Auditorium, 3333 Coyote Hill Rd, Palo Alto, CA 94304, USA
Fee: free for members, $15 for nonmember
Register at http://www.brownpapertickets.com/event/2884603

Program Description
Are you interested in tackling complex, multi-faceted problems at the interface between science and policy?

A career in policy-making and public service offers the opportunity to be the conduit between the worlds of science and policy. To learn more about what a career in public policy and government involves, join us for an interactive session with Erika Bustamante, Director of State Government Relations at Stanford University, and Rebecca Newhouse, Environmental Scientist at the US EPA.

Speaker Bios
Erika Bustamante manages the activities and relationships with state governmental bodies related to regulatory and legislative issues impacting Stanford's mission. Previous to joining Stanford, Bustamante worked as the Legislative Director for Assembly Member Luis Alejo. She is also a former California Science and Technology Policy Fellow. Bustamante holds a BS in Molecular, Cell and Developmental Biology from UCLA and a Ph.D. in Developmental Biology form Stanford University.

Rebecca Newhouse is an Environmental Scientist in the Air Division at US EPA, Region 9. Before joining the EPA, Rebecca worked as a committee consultant for the California State Senate Environmental Quality Committee. Prior to working for the State Legislature, she was a 2011/12 Science and Technology Policy Fellow with the California Council on Science and Technology. Rebecca has a PhD from UC Santa Cruz in chemistry and a bachelor's degree in biochemistry from Western Washington University in Bellingham.
****

Biomedical Engineering Society, Wednesday, March 29, 2017

Event: 8th Annual Bay Area Biomedical Device Conference-Medical Devices in the Connected World
Date and Time: Wednesday, March 29, 2017, 7:30 am
Location: SJSU Student Union Ballroom, San Jose State University
Please take advantage of the reduced early registration which ends on March 16, 2017 at 5:00 pm. PST.
Visit our website at www.biomedconference.org for more details or email info@biomedconference.org if you have any questions.
Register at http://www.biomedconference.org/register

Event Description
The Biomedical Engineering Society at San Jose State University (SJSU) is happy to announce the 8th Annual Bay Area Biomedical Device Conference!
Some exciting features of this conference include:
● An expert biomedical plenary speaker
● Informative parallel sessions
● Interactive Industry & CEO Panels
● Student Research Posters
● Sponsors and representatives from various biomedical companies
● Wine & cheese networking reception
● & More!
****

Bioscience Forum, Wednesday Evening, March 29, 2017

Topic: "Leveraging Biotech's Novel Platforms to Tackle Global Health: A Unique Business Model to Overcome Financial Barriers"
Speaker: Eric Easom,Vice President Neglected Disease R&D, Anacor Pharmaceuticals (Acquired by Pfizer June, 2016)

Date and Time: Wednesday, March 29, 2017, 6:00 PM - 9:00 PM
6 pm - 7 pm networking
7 pm - 8 pm dinner
8 pm - 9 pm presentation
Location:The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080, USA
Join us from 6-9 pm to network and hear the latest scientific and business advances in the San Francisco Bay Area biotech community

Event Registration ($3 service fee will apply)
Pre-Registration
$50.00
On-Site Registration
$60.00
Pre-Registration ends Monday, March 27th, at 9 pm
Cash or check accepted on the day of the event
$10 discount for full-time students
Register at http://biosf.org/
Or you can pay with a check made out to "BioScience Forum" and sent to:
BioScience Forum
1442A Walnut Street, #308
Berkeley, CA 94709-1405
Please do not mail checks later than Thursday, March 23rd
If paying with check, do not complete online registration with Cvent

Topic Description
The world's poorest populations are disproportionately affected by neglected diseases, such as tuberculosis (TB), malaria, visceral leishmaniasis, Chagas disease, human African trypanosomiasis (sleeping sickness), and filarial worms. The current standards of care are difficult to administer, often have significant toxicities, and are increasingly becoming less effective due to the development of resistance. Despite the fact that these diseases cause significant morbidity and mortality worldwide, there has been little investment by industry in developing new therapies due to expectations of low financial returns.

In early disease screenings, Anacor's boron chemistry platform proved to be particularly well-suited for developing treatments for these types of infectious diseases. Though the company felt a responsibility to apply its technology to neglected disease R&D, it was venture-backed and pre-revenue. Devoting time and money to the pursuit of new therapies for complex, unprofitable global health markets could create a conflict with the objectives of its investors. To overcome this, Anacor devised a business plan to leverage non-dilutive funding sources to underwrite this important work. Over the past 10 years, this business model has funded the development of one of the most promising pipelines in this space, with two clinical candidates for African sleeping sickness and TB and the potential for five or more in the next 1-2 years. Over $50 million of funding to subsidize this R&D was raised from non-profits, government agencies, companies and foundations such as the Bill & Melinda Gates Foundation and the Wellcome Trust. Anacor’s drug discovery capabilities were supplemented with more than 50 external collaborators from academia, nonprofits and pharmaceutical partners that provided additional expertise in infectious disease biology. Eric will be sharing the story of Anacor’s science, its business model, and the strategic value that can be gained from pursuing R&D programs in neglected diseases. The hope is to inspire others by example and

demonstrate the depth of potential to treat some of the world's most devastating infectious diseases.

Speaker Bio
Eric is the Vice President for the Neglected Diseases Initiative at Anacor Pharmaceuticals Inc., overseeing the company's research and development efforts to advance new therapeutics for the treatment of neglected diseases. He brings 26 years of pharmaceutical and biotech experience from various leadership roles in R&D program and alliance management, business development, marketing, sales, finance, and manufacturing from his time at Eli Lilly and Company, MedImmune, McKesson, and InteKrin Therapeutics.

Eric Easom served as a member of the Board of Directors at the Infectious Disease Research Institute (IDRI) from 2007-2014 and as Chairman from 2010-2013.

Eric received an MBA from Indiana University and a BS and Masters of Engineering from the University of Louisville.
****

PBSS Workshop, Thursday Afternoon, March 30 2017

Event: "Best CMC Practices for Successful Drug Development and Commercialization: Leveraging QbD and risk-based strategies for efficient CMC development"
Speakers: Prabu Nambiar, Edward Ciolkowski, James Bush (Syner-G Pharma Consulting)
Date and Time: Thursday, March 30, 2017, 12:30-5:00 pm Registration fee (US$): Regular: $125; Academic: $75; For unemployed & students: $25; For vendor-show reps: $25; For major-sponsor rep (incl lunch): $0; For others, details available upon online login.
Location: SF Bay Area: Foster City Crowne Plaza
Registration: http://www.pbss.org/aspx/eventInfo.aspx?eID=528
Further Information:
Registration deadline: 3/28/2017 (it will close sooner if the seating cap is reached)

support@PBSS.org
www.PBSS.org
****

AWIS NCC Workshop, Saturday, April 1, 2017

Workshop: "Leadership by Design: Using Design Thinking to transform your Career"
Workshop Leader: Christopher Ireland
Date and Time: Saturday, April 1st,8:30am-2:00pm

8:30-9:00	Check in and breakfast
9:00-9:15	Opening remarks
9:15-12:00	Leadership by Design
12:00-12:45	Networking lunch
12:45-1:45	Leadership Panel
1:45-2:00	Closing remarks

Location: Genentech, Inc. (View), Room B31-1A, 310 DNA Way, South San Francisco, CA 94080
Registration
http://ebawis.us11.list-manage.com/track/click?u=0bfd730afa47c08495b877f1b&id=2dd81fdafe&e=e5488d3ca3
Sign up for the workshop today!

Fees:
Register for tickets now for a reduced price ($35 for members, $50 for non-members).
http://ebawis.us11.list-manage1.com/track/click?u=0bfd730afa47c08495b877f1b&id=90c3499acb&e=e5488d3ca3

Workshop Description
Do you want to become a successful leader in a fast-paced and rapidly changing work environment? Join us for an interactive workshop on Design Thinking with Christopher Ireland, the coauthor of "Rise of the DEO". Here you will learn a unique perspective on leadership and gain the innovative strategies and skills you need to unleash your inner leader.

Leader Bio
Christopher Ireland worked for 20 years growing and developing Cheskin, a consultancy focused on product and market design innovation. Under her leadership as CEO, the company expanded into global markets, opened four offices, completed two successful mergers and gained a reputation for top quality performance serving a range of high growth clients including Microsoft, Intel, HP, Motorola, Pepsi and more. Christopher and her partners successfully sold Cheskin late in 2007.

Ms. Ireland has an M.B.A. from the Andersen School of Management (UCLA). She currently teaches graduate design students at California College of the Arts in San Francisco and Continuing Studies students at Stanford University. In 2013, she co-authored Rise of the DEO, (New Riders Press) a book examining contemporary leadership traits. She has lectured extensively on the topics of design, human behavior and corporate leadership.

****

QB3, Monday MidDay, April 3, 2017
Topic: "How Federal Politics Impact Funding for Science and Startups"
Speaker: Ryan Davison, government affairs manager at the American Chemical Society in Washington, DC
Date and Time: Monday, April 3, noon to 1:00 pm
Location: Room N-114, Genentech Hall, UCSF Mission Bay
Fee: $10 general admission
Register at https://www.eventbrite.com/e/qb3-seminar-ryan-davison-acs-how-federal-politics-impact-funding-for-science-and-startups-tickets-32633279016?mc_cid=84bb71f0fb&mc_eid=cb4c38a44a

Topic Description
Washington politics usually seem far removed from life at the lab bench. But issues at the federal level can affect what funds the government makes available for grants of all types, from R01 to SBIR. If you understand the ever-changing landscape, you may be able frame your application so it is successful, or expand into research areas that are more likely to get funded. To get the big picture from Ryan Davison, government affairs manager at the American Chemical Society in Washington, DC, join us on April 3. Ryan will provide a general political update, highlight specific pieces of legislation meaningful to researchers, discuss key congressional committees, and explain how Republicans and Democrats view the economy differently. Additionally, Ryan will take a look at SBIR and proof-of-concept funding, and highlight areas likely to get funding in the near future.

Speaker Bio
Dr. Ryan Davison is currently the Manager of Government Affairs at the American Chemical Society where he advocates for legislation that supports the chemical industry. Dr. Davison manages advocacy and policy development on priority issues including manufacturing, tax and trade, intellectual property, patents, biomedical research, innovation and competitiveness, agency funding, and appropriations. Most of his time is spent on Capitol Hill meeting with lawmakers and their staff, attending Congressional hearings and mark-ups, and monitoring bills relevant to the chemical enterprise. Ryan possesses a distinct background of policy and science experience. Before joining the ACS he worked as a policy Fellow at the National Academy of Sciences, served as Biosecurity Analyst at the Federation of American Scientists, was a post-doctoral Fellow at Georgetown University, and an adjunct professor at George Washington University. He holds and Bachelor's and Master's degree in Psychology from Appalachian State University, a Ph.D. in Neuroscience from the University of Alabama at Birmingham (UAB), and is in a unique position to be able to personally highlight the importance of innovation and research to members of Congress and their staff.
****

JLABS, Thursday, April 6, 2017

Event: MedTech Innovator 2017: JLABS Pitch Event
Date and Time: Thursday, April 6, 2017, 9:00 am – 5:00 pm
Agenda:
9:00am - 9:30am | Registration Opens and Networking
9:30am - 10:00am | Welcome & Introduction
10:00am - 12:30pm | Pitch Session (4 companies)
12:30-1:30pm | Networking Lunch
1:30pm - 4:00pm | Pitch Session II (4 companies)
4:00pm - 4:30pm | Success Stories Feature
4:30pm - 5:00pm | Award Presentation
*Companies must have applied to pitch ahead of time and be approved. The application deadline is Feb 28.
Location: JLABS @ SSF, 329 Oyster Point Blvd., Floor 3,South San Francisco, CA 94080
Fees: Free
*Companies must have applied to pitch ahead of time and be approved. The application deadline is Feb 28.
Apply Now to Pitch at JLABS
The MedTech Innovator SF Pitch Event is opent to all attendees. Startups interested in pitching are encouraged to apply at http://medtechinnovator.org/apply.
See details at https://www.eventbrite.com/e/medtech-innovator-2017-jlabs-pitch-event-tickets-31169197910?aff=weekly

Event Description
About MedTech Innovator 2017
MedTech Innovator is the industry's nonprofit global competition and accelerator. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator is the largest platform of its kind, providing participants with broad exposure and mentorship from the leading players in the medtech industry. In 2017, MedTech Innovator will give out over $500K in cash prizes.

MedTech Innovator Criteria
MedTech Innovator seeks early to mid-stage startups, including medical device, diagnostic, and digital health technologies addressing the following industry-selected themes:

Chronic Disease Management
Cognitive Devices and Platforms
Consumer Healthcare
Healthcare Efficiency and Cost Reduction
Infectious Disease Management
Next-Gen Surgical
Patient Safety and Satisfactio
Population Health; Precision and Personalized Medicine and Technology Enabled Services

Program Participant Benefits
Companies selected to participate in the MedTech Innovator Accelerator receive:
Mentorship from leading investors, manufacturers, providers, payers, IP, regulatory and reimbursement professionals, and others.
Exclusive participation in the three-day MedTech Innovator Accelerator Kick-Off in San Francisco.
A chance to compete onstage for $500,000 in cash prizes and more.

****

Bio2Device Group, Tuesday Evening, April 11, 2017

Topic: "Wicked questions for Digital Health "
Speaker: David Kerr, MD, Director of Research and Innovation, William Sansum Diabetes Center
Date and Time: Tuesday, April 11, 2017 - 6:00pm
Location: Wilson Sonsini Goodrich & Rosati - 650 Page Mill Road, Palo Alto
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Register at www.bio2devicegroup.com

Speaker Bio
Dr. David Kerr is Director of Research and Innovation at the world-renowned William Sansum Diabetes Center based in Santa Barbara, CA. Before moving to the US in early 2014, for many years, he was a Consultant Physician in internal medicine and diabetes at the Bournemouth Diabetes and Endocrine Centre in the United Kingdom.

Dr. Kerr is creator and co-founder of www.DiabetesTravel.org and www.excarbs.com,author of more than 200 peer-reviewed articles (Google Scholar h-index of 40), Editor-in-Chief for Diabetes Digest, and a regular blogger for the British Medical Journal on the subjects of technology and health. He is also the digital health lead for the Diabetes Technology Society and was previously Editor of the Journal of Diabetes Science and Technology.

Dr. Kerr is a Fellow of the Royal College of Physicians of Edinburgh, Visiting Professor at Bournemouth University, and for many years has held a Gold Clinical Excellence Award from

the National Health Service in the United Kingdom. You can follow him on Twitter @Godiabetesmd.

****

WIB, Wednesday Evening, April 12, 2017

Subject: WIB-National Webinar "Risky Business: Mitigating Risk in the Life Sciences"
Speaker: Gretchen Stup, Sr. Consultant at Latham Biopham Group
Date and Time: April 12, 2017, 1:00 p.m. – 2:00 p.m. EST*
*- Please note this webinar's time is listed in Eastern Standard Time.
Pricing Information
Members: Free
Non-Members: $30
* - Registrants will be sent a specific GoToMeeting link to access the webinar. Please be sure to click on the link before the webinar to ensure the program is properly installed on your computer.
Register at http://womeninbio.org/eventdetails.aspx?EventId=30877
Registration Deadline
April 11, 2017
Registrants will receive a webinar link via confirmation email

Webinar Description
Inviting. Supporting. Succeeding.
All projects present risk, and successful project managers recognize that it is vital not to avoid risks, but to understand them. Risk management is the process of identifying, assessing, mitigating, and controlling the known risks in order to increase the probability of meeting your project objectives. By planning for unexpected events, you can be ready to respond if they arise. This webinar will be led by Gretchen Stup, Senior Consultant, Latham BioPharm Group, and will bring to light the importance of Risk Management as well as introduce methods and tools that can be implemented to ensure a successful risk management process. Gretchen will utilize a slide presentation and will review specific examples to help illustrate the key concepts of Risk Management. The presentation will help you understand how to identify what can go wrong, how to assess a risk events probability and impact, and what to do to lessen the probability or impact of a risk event occurring. Real-world examples and considerations from the speaker's professional experience will be highlighted during the webinar. In addition, there will be time allotted for questions and answers at the conclusion of the webinar.
This course will result in up to one hour of PMI-approvable Professional Development Units (PDUs) for the project management field.
Learn more and register for this event.

Speaker Bio
About Gretchen Stup: Gretchen has over 16 years of experience in the management of government contracts, and over 18 total years of experience working in a scientific environment. She is currently a Sr. Consultant at Latham Biopharm Group where she provides program management and systems integration support to government and client related projects. Prior to this, she served as a Sr. Project Manager for DynPort Vaccine Company (DVC) where she managed a >$350 M DoD advanced vaccine development contract and a smaller NIAID R&D contract. She has experience in total project lifecycle management, with a focus on managing and integrating the activities of numerous functional areas, including finance, manufacturing, nonclinical, quality, clinical, and regulatory personnel, and managing project related subcontractors. Prior to working in

Program Management, Gretchen co-developed and implemented DVC's comprehensive Risk Management program. She has a Bachelor of Science degree from Shepherd University and is a Project Management Professional (PMP) as certified by the Project Management Institute.
Walk-Ins Accepted?
Walk-ins are not accepted – be sure to register early!
****

JLABS, Tuesday Morning, April 18, 2017

Topic: "Meet with the Gates Foundation"
Speaker: Charlotte Hubbert, PhD | Partner, Gates Foundation Venture Capital
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Date and Time: Tuesday, April 18, 2017, 10:30 am
Agenda:
10:30am | Registration & Networking
11:00am | Company Presentation and Q&A
11:45am | Lunch & Networking
12:45-5:00pm | One-on-one Meetings*

*Companies must have apply ahead of time and be approved for a one-on-one meeting. Application period ends March, 13, 2017. Apply Here.
Fees:
Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until 12:30pm on April 18th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period will close on March 13, 2017. Your application will be reviewed and you will be notified of acceptance by March 30, 2017. Acceptance of one-pn-one meeting is not guaranteed as all applications must be approved
Registration at https://www.eventbrite.com/e/meet-with-the-gates-foundation-tickets-29533732188?aff=weekly

Program Overview:
The path out of poverty is paved with access to quality healthcare. Do you have solutions that will make a difference? The Bill & Melinda Gates Foundation is advancing science and technology to save lives in developing countries. The Foundation works with partners to deliver proven tools—including vaccines, drugs, and diagnostics—and discover ground breaking new solutions that are affordable and reliable. Focus areas for investments center on infectious diseases including HIV, polio, TB, dengue and malaria, as well as diagnostics and health IT ideas that bring health interventions to people who need them most.

Charlotte Hubbert, Partner with Gates Foundation Venture Capital, will be in attendance to provide an overview presentation on the Foundation's key areas of interest and venture investment philosophy. Gates Foundation Venture Capital operates under the Program Related Investments group at the Bill & Melinda Gates foundation, which manages a $1.5B allocation for private sector investment. Charlotte will be on hand to meet with a handful of applicants one-on-one after the presentation. To be considered for a one-on-one meeting complete the information required at the link below.

Speaker Bio
Charlotte Hubbert is a Partner with Gates Foundation Venture Capital, investing innovative technologies that support The Bill & Melinda Gates Foundation initiatives in Global Health and Agriculture. Prior to joining the Gates Foundation, Charlotte was a Vice-President at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices at all stages of development. She was BOD observer at Cardeas Pharma and Alder Biopharmaceuticals. Charlotte started her career in early stage biotech investing at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte currently serves as an observer on the board of directors of Synlogic, Sera Prognostics and Lodo Therapeutics.
Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stemcells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).
Connect with Charlotte: Connect on LinkedIn

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

****

EMBS, Wednesday Evening, April 19, 2017

Topic: "Study of Fluorescence Spectroscopy Guided Optical Biopsy Needle for Prostate Cancer Diagnosis"
Speaker: Amir Tehrani, Chief Executive Officer, Precision Biopsy, LLC
Date and Time: Wednesday, April 19, 2017, 7:30 pm
Location: Room M-114, Stanford University Medical School (see campus map at link below)

Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations, self-serve)

http://maps.stanford.edu/sites/all/lbre-shared/files/maps/files/shared/file/maps_records/Parking_And_Circulation_Map.pdf
Parking is usually free after 5 PM at Roth Way Garage, which is at the corner of Roth Way and Campus Drive West (E-7) on the map. The Stanford Hospital Cafeteria is near the Emergency entrance, at D-6 on the map. The Medical School is across Campus Drive West from Roth Way Garage, and Room M114 is accessible from outside the building at E-6 on the map.

Topic Description
Current prostate biopsy cores have a very low diagnostic yield. These biopsies often fail to diagnose prostate cancer since 90% of cores are histopathologically classified as benign. The concentrations of endogenous fluorophores in prostate tissue vary with disease states. Thus, fluorescence spectroscopy could be utilized to quantify these variations for identification of malignant lesions. We investigated clinical feasibility of a 14 gauge (1.98 mm) optical biopsy needle guided by fluorescence spectroscopy for real-time in vivo prostate cancer diagnosis. Built-in optical sensor has 8x100μm fibers for tissue excitation and a single 200μm fiber to collect spectral data. Custom-made fluorometer has 2 light-emitting diodes at 290 and 340 nm and a spectrometer. User interface for fluorometer operation and data collection was developed using LabView software. Each spectral data acquisition required ~2 seconds. The in vivo biopsies were performed during radical retropubic prostatectomy surgery on the exposed prostate with blood flow to the gland intact. A tissue biopsy core was obtained from each biopsy site after acquisition of spectral data. Above procedure was repeated ex vivo after surgical excision of the prostate. Biopsy cores were histopathologically classified as either benign or malignant and correlated with corresponding spectral data. Partial Least Square analysis was performed to determine diagnostically significant principal components as potential classifiers. A linear support vector machine and leaveone-out cross validation method was employed for tissue classification. Thirteen patients were consented to the study. Histopathological analysis found cancer in 29/208 in vivo and 51/224 ex vivo viable biopsy cores. Study results show 72% sensitivity, 66% specificity, and 93% negative predictive value for in vivo and 75%, 80%, and 93%, respectively, for ex vivo malignant versus benign prostatic tissue classification. Optical biopsy needle has a very high negative predictive value to indicate benign tissue while sufficient sensitivity for targeting areas suspicious for cancer within the prostate gland. Hence, the optical biopsy needle can increase the diagnostic yield of prostate biopsies with consequent improvement in patient care.

Speaker Bio
Precision Biopsy is led by CEO Amir Tehrani, who has over 20 years' of experience in management and operations, strategy, business development, marketing, design and development for Fortune 500 and start-up medical device companies. Prior to Precision Biopsy, Amir was the President and CEO of Amaranth Medical, Inc., a bioabsorbable stent company. He has been instrumental in the formation and financing of several medical device companies, including Inspiration Medical, Inc., Corventis, Inc. (acquired by Medtronic, Inc.), Spinal Modulation, Inc., (acquired by St. Jude Medical), Sonitus Medical, Inc., and RODO Medical, Inc. Amir also led successful investments and acquisition in the medical technology sector at Guidant Compass Group. He also held several leading marketing and engineering positions at Guidant Vascular Intervention, St. Jude Medial CRM Division, Ventritex, Inc., (acquired by St. Jude Medical), and MiniMed, Inc. (acquired by Medtronic, Inc.). Amir holds a BS in Electrical Engineering from the University of Idaho and an MS in Biomedical Engineering from California State University in Sacramento, CA.

****

PBSS Symposium, Monday, April 24, 2017

Topic: "Mechanistic Drug Metabolism for Drug Candidate Optimization – A Mini-symposium for Medicinal Chemists and DMPK Scientists"
Organizers: Cyrus Khojasteh and Donglu Zhang (Genentech)
Date and Time: April 24, 2017, 8:45-17:00
Location: Crowne Plaza, Foster City, CA
Registration fee (USD): Minisymposium fee: $195;
Registration: http://www.PBSS.org
Registration deadline:4/20/2017 (it will close sooner if the seating cap is reached)

Topic Description
Drug metabolism and pharmacokinetics (DMPK) plays an integral role in drug discovery. At drug discovery stage, mechanistic drug metabolism studies contribute to generating drug candidates with optimal ADME properties and in some cases it allows for overcome potential drug development obstacles such as toxicity and DDI that are often encountered in drug discovery and development. In this one-day symposium, multiple examples will be presented to illustrate the utilities of mechanistic drug metabolism in moving discovery and development programs forward. Medicinal chemists and drug metabolism scientists should greatly be benefited from participating in this symposium.

Tentative topics and speakers:
Morning: 8:45-12:00
Overview on drug metabolism and its role in lead optimization - Cyrus Khojasteh, Genentech
Hepatocyte spheroid models and applications in drug metabolism - Jinping Gan, BMS
Sponsor presentation
Drug metabolism tools to assess bioactivation potential of drug candidates - minimizing metabolism-related DILI or genotoxicity - Zhoupeng Zhang, Merck
Prediction of circulating drug metabolites - Ming Hu, University of Houston

Afternoon: 1:15-5:00
Inhibition of endogenous metabolic pathways leading to toxicities - Donglu Zhang, Genentech
Sponsor presentation
Discovery of Bioavailable Pim Inhibitors by Mitigating Intestinal Metabolism – Gina Wang, Genentech
Metabolism-based structure-activity relationship analysis for identification of a PI3K inhibitor clinical candidate devoid off target hepatotoxicity - Raju Subramanian, Gilead
Minimizing reversible and time-dependent CYP inhibition of NAMPT (nicotinamide phosphoribosyltransferase) inhibitors - Mark Zak, Genentech
Carboxylic acid bioactivation via glucuronides/acyl CoA's and application in drug discovery – Mark Grillo, Amgen
****

JLABS Bay Area, Tuesday Mid Day, May 2, 2017

Topic: "Money Matters - Insider Tips on Raising Money"
Speaker: Julie Papanek, Partner, Canaan Partners
Date and Time: Tuesday, May 2, 2017, 10:30 am – 1:00 pm
Agenda:
10:30 AM | Registration and Networking
11:00 AM | Presentation

11:30 AM | Q&A
12:00 PM | Food and Networking
1:00 PM | Program Close
Fees:
$25 | General Public
$15 | Student
$45 | At the door
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor,South San Francisco, California
Order at https://www.eventbrite.com/e/money-matters-insider-tips-on-raising-money-tickets-32167293240?aff=weekly

Speakers Bio
Julie Papanek is a Partner at Canaan Partners where she concentrates on biopharmaceutical, digital health and consumer medical device investments. Julie currently sits on the board of Protagonist Therapeutics (PTGX) and has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development.

Julie earned her MBA from Stanford¹s Graduate School of Business, MPhil from Cambridge in BioScience Enterprise and B.S. from Yale in Molecular Biophysics and Biochemistry.
****

BioPharma PM Conference, Monday-Tuesday, May 22-24, 2017

Event: Stepping Up and Stepping Out
Dates: Monday, Tuesday and Wednesday, May 22-24, 2017
Program:
May 22
5:00-7:00PM: Registration and Opening Networking Reception
May 23
7:30-9:00AM: Registration and Breakfast Networking
9:00AM-5:00PM: Conference Presentations, Panels, Workshops
5:00-7:00PM: Evening Networking Reception
May 24
7:30-9:00AM: Breakfast Networking
9:00AM-2:30PM: Conference Presentation, Panels, Workshops
2:30PM: Conference Conclusion
Location: San Mateo Marriott San Francisco Airport, 1770 South Amphlett Boulevard, San Mateo, CA 94402
Registration: Early Bird Registration (through March 31): $695 (plus payment processing fees); Regular Conference Registration (after March 17): $895 (plus payment processing fees); All registrants will receive a complimentary one-year BioPharmaPM Network membership (a $50 value).
Register at https://www.eventbrite.com/e/2017-biopharmapm-conference-tickets-31937261208

Event Description
Please join us for the 2017 BioPharmaPM Network Conference! We are planning an exciting program for you. Below are a few of our featured speakers, panelists, and trainers who will speak on diverse topics such as managing your career in alignment

with your values, leadership development in project management, and how you can solve problems inhibiting project success easily and effectively.

Speakers: William Schiemann, Founder and CEO of Metrus Group and Author; Jean Lee, Ph.D., Vice President, Portfolio and Project Management at Pfizer Global Product Development; Michael Young, Chief Learning Officer and SVP of Education at the The Medicines Company;Mark Velligan, Senior Director of Portfolio Management and Operations at Genentech;Trevi Wormley, Managing Director and Chief Solution Engineer at TJ Strategy Group, LLC

We hope you will join us at the San Mateo Marriot in San Francisco May 22-24 and be a part of the only non-profit organization solely committed to project management best practices, development, and networking for biopharma project and program managers.

FAQs
How can I contact the organizer with any questions?
For questions, please contact Kelly Magnuson at kmagnuson@biopharmapm.org
How do I make room reservations?
We are holding a few rooms at a discounted rate with the San Mateo Marriott. If you require a room, please email Kelly Magnuson at kmagnuson@biopharmapm.org for details.
****

JLABS, Tuesday Morning, May 23, 2017

Topic: "Rough seas or smooth sailing? Navigating Collaboration Agreements"
Speakers:
Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
William J. Newell | CEO, Sutro Biopharma
Moderator: Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Date and Time: Tuesday, May 23, 2017 from 9:00 AM to 11:30 AM (PDT)

Agenda:
9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Fees:
$25 | General Public
$15 | Student
Order at https://www.eventbrite.com/e/rough-seas-or-smooth-sailing-navigating-collaboration-agreements-tickets-32071988180?aff=weekly

Event Details
How do you develop a smart collaboration agreement? An effectively written collaboration agreement builds and strengthens a productive scientific relationship by allowing parties to enter into a mutually beneficial relationship.

How do you make sure the agreement will fit your company objectives? An effective agreement should be clear, to both the research workers and managers of both parties, laying the groundwork for moving the results of research toward commercialization. It addresses the nature of the collaboration, the responsibilities and obligations of each party, the desired outcomes and next steps beyond the currently contemplated research.

At this event, we will walk through building components of a collaboration agreement, point out and discuss key terms and provisions that help make a quality agreement. The talk with provide real world examples and focus on the following topics:
Intro to Collaboration Agreements / General provisions
Statement of objectives/work
Budget
IP
Restrictions and opportunities created by agreements
Real world examples from panel members
The panel members will share real life experiences through the R&D collaboration process and beyond. The workshop will examine key types of provisions and their effects on future development and funding opportunities. This "how to" workshop is geared towards life sciences startup
Guests will be provided supporting materials including:
Key provisions guide
Sample Collaboration agreements
This event is being hosted in conjunction with Deloitte. Deloitte is deeply committed to the life sciences industry. As an advisor to many leading health care and life sciences organizations, Deloitte has been instrumental in developing and implementing many strategies that helped shape the evolution and long-term success of this industry. At Deloitte, we serve from early-stage companies to the world's largest players. We know where you go and we can help you to realize your dreams. As with all our events, the "How to…Workshop" is informal and interactive so bring your questions with you!

Speakers' Biographies:

Angela Rusakova | Lead Client Service and Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a focus on the life sciences industry. She works with companies in all stages of growth, from start-ups to SEC registrants. Her technical background includes complex accounting issues such as revenue recognition, equity, derivatives, stock-based compensation, and acquisitions. Angela has been involved in financing and M&A transactions, including initial public offerings, offerings in leveraged buyouts, and several secondary shares offerings. She has extensive international experience and is a certified public accountant in the United States and the United Kingdom. Angela also served as a CFO before returning to public accounting in 2003.

Yelda Kaya | Sr. Director Transactions, Johnson & Johnson Innovation
Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.
Leveraging a diverse career practicing emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of

successfully leading, structuring, negotiating and executing complex deals over the last 10 years.
Yelda joined the Johnson & Johnson family from GSK's worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.

William J. Newell | CEO, Sutro Biopharma
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. During her career she has work on over 45 collaboration agreements helping shape effective opportunities for early stage companies. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.
****

JLABS, Tuesday Morning, June 20, 2017

Event: "Meet with… Novartis Venture Fund"
Date and Time: Tuesday, June 20, 2017 from 10:30 AM to 1:00 PM (PDT)
Agenda:
9:00 AM | Registration, Breakfast, and Networking
9:30 AM | Components of a collaboration agreement
10:00 AM | Panel Discussion: Implications of Components
11:00 AM | Q&A
11:30 AM | Program Close

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due May 19, 2017. Apply Here.
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Ticket Information
Fees:

Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 20 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Apply to meet one-on-one with representatives from Novartis Venture Fund. Your application will be reviewed and you will be notified of acceptance on Monday June 6, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Event Details
Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with… Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.

On June 20th Principal Christine Brennan and Life Sciences Investment and Operations Professional Giovanni Ferrara of the Novartis Venture Fund (NVF)team will be in attendance to give an overview presentation about the fund's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.

Program Overview:
The Novartis Venture Fund founded in 1996, currently manages over $750 Million in committed capital, and has investments in ~40 portfolio companies globallyb>. NVF's strategy is to build a diverse portfolio of life science companies, across:
Biotechnology/biopharma
Medical device/diagnostics
Digital/eHealth
NVF is stage agnostic and engages in seed investments as well as later-stage investments, typically investing up to $15 - $20 million over the life of the company. In investing, NVF looks for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency.

Following the presentation, don't miss this opportunity to introduce yourself to the team during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Novartis Venture Fund will provide an intimate forum to discuss your company

Speaker Bios:
Christine Brennan | Principal, Novartis Venture Fund
Dr. Brennan joined the Novartis Venture Fund in November 2013. Prior to joining Novartis Venture Fund, Dr. Brennan spent 3 years at Vitae Pharmaceuticals as Chief Business Officer responsible for strategy & business development. Prior to Vitae, she spent 5 years at Novartis Institutes for BioMedical Research in Strategic Alliances, most recently as Executive Director and Head of Strategy & Operations. Prior to

Novartis, she held positions in business development and marketing at the biopharmaceutical companies, EnVivo Pharmaceuticals (now FORUM Pharmaceuticals), Biovail (now Valeant Pharmaceuticals) and Cogent Neuroscience. In addition, she was Director atFidelity Biosciences Group (now F-Prime Capital Partners), a venture capital company. She received her Ph.D. in neuroscience from Dartmouth Medical School in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.

Giovanni Ferrara | Life Sciences Investment and Operations Professional, Novartis Venture Fund